Risk factor
Considerable default risk
Profitability factor
Very poor margins and returns
About
Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, trading
Target Price
The average target price of VITR.ST is 170 and suggests 50% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell